Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
In pre-approval trials, there was an increased incidence of mild, transient elevations of liver aminotransferases in study subjects treated with dimethyl fumarate (DMF). To evaluate post-marketing cases of drug-induced liver injury associated with DMF. We identified 14 post-marketing cases of clinically significant liver injury. Findings included newly elevated serum liver aminotransferase and bilirubin levels that developed as early as a few days after the first dose of DMF. The pattern of liver injury was primarily hepatocellular. No cases resulted in liver failure. Health professionals should be alerted to possible serious liver injury in patients receiving DMF.